What's in Amylyx Pharmaceuticals Inc.'s pipeline?

Amylyx Pharmaceuticals Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Amylyx Pharmaceuticals Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amylyx-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Amylyx Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Amylyx Pharmaceuticals Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AMX0035	AMX0035	phase 3	Neuroprotective agent; combination therapy	ER stress pathway, mitochondrial stability, neuroinflammation	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Amylyx Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Amylyx Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amylyx-pharmaceuticals-inc. Accessed 2026-05-16.